Intravenous ferric carboxymaltose accelerates erythropoietic recovery from experimental malarial anemia.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22357662.
- Also identified by DOI 10.1093/infdis/jis020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Iron restriction has been proposed as a cause of erythropoietic suppression in malarial anemia; however, the role of iron in malaria remains controversial, because it may increase parasitemia. To investigate the role of iron-restricted erythropoiesis, A/J mice were infected with Plasmodium chabaudi AS, treated with intravenous ferric carboxymaltose at different times, and compared with untreated controls. Iron treatment significantly increased weight and hemoglobin nadirs and provided enhanced reticulocytosis and faster recovery, compared with controls. Our findings challenge the restrictive use of iron therapy in malaria and show the need for trials of intravenous ferric carboxymaltose as an adjunctive treatment for severe malarial anemia.
Medical subject headings
- Anemia, Iron-Deficiency
- Erythropoiesis
- Ferric Compounds
- Growth Substances
- Malaria
- Maltose